Umbilical cord mesenchymal stromal cells (UCMSCs) [1] have emerged as a promising therapeutic strategy for preventing and treating immune-mediated transplant rejection. Their immunomodulatory properties, low immunogenicity, and ability to regulate both innate and adaptive immune responses make them ideal candidates for improving graft survival while reducing reliance on systemic immunosuppressants,...

Li Yun et al.
BMC Ophthalmology 2025; 26(1): 21
Lire la suite

Pseudomyxoma peritonei (PMP) is an extremely rare peritoneal malignancy, with an estimated incidence of one to three cases per million people per year worldwide [1, 2]. It typically originates from a perforated mucinous appendiceal neoplasm in which mucinous neoplastic cells disseminate and implant on the peritoneal surface, leading to progressive peritoneal gelatinous ascites [3] The optimal treatment...

Nikoupour Hamed et al.
Journal of Medical Case Reports 2025; 20(1): 29
Lire la suite

Acute Myeloid Leukaemia(AML), and Myelodysplastic Syndrome (MDS) are severe haematological malignancies affecting the bone marrow. Without treatment, AML progresses rapidly and can be fatal within months. Even with modern therapies, five-year survival rates range between 15–25% for AML [1], while median survival for patients with lower-risk and higher-risk MDS is 3 to 10 years, and less...

Bushaway Samuel et al.
BMC Cancer 2025; 26(1): 94
Lire la suite